Compare Fox Corp Class B (FOX) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Heron Therapeutics Inc — how do they compare? Fox Corp Class B trades at $55.42 (market cap $25.36B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Fox Corp Class B is far larger — about 372.9× Heron Therapeutics Inc's market cap, and Fox Corp Class B pays a 1.02% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Heron Therapeutics Inc for 35 Days on average.
| FOX | HRTX | |
|---|---|---|
Market Cap | $25.36B | $68.01M |
Volume | 886,620 | 1,891,941 |
Sector | Media | Health |
52-Week High | $67.76 | $1.49 |
52-Week Low | $44.39 | $0.27 |
Typical Hold Time | 75 Days | 35 Days |
Enterprise Value | $28.72B | $174.75M |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $56.13, up 0.27% today, with a bullish technical signal from moving averages and a consensus analyst price target of $84.75 implying significant upside. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate. Fundamentals show robust growth, with 2025 revenue reaching $16.30 billion and net income margin improving to 13.88%.
The outlook is positive given valuation multiples below industry averages and consistent earnings outperformance, but risks include a projected net cash flow decline in 2026 and competitive pressures in the media sector. Investor sentiment is mixed, with analyst ratings nearly evenly split between Buy and Hold.
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
